{
  "source": "PA-Notification-Nemluvio.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1478-1\nProgram Prior Authorization/Notification\nMedications Nemluvio® (nemolizumab-ilto)\nP&T Approval Date 6/2025\nEffective Date 9/1/2025\n1. Background:\nNemluvio (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the\ntreatment of adults with prurigo nodularis and for the treatment of adults and pediatric patients\n12 years of age and older with moderate to severe atopic dermatitis in combination with topical\ncorticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with\ntopical prescription therapies.\n2. Coverage Criteriaa:\nA. Atopic Dermatitis\n1. Initial Authorization\na. Nemluvio will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe atopic dermatitis\n-AND-\n(2) Will be used in combination with topical corticosteroids and/or calcineurin\ninhibitors when the disease is not adequately controlled with topical prescription\ntherapies\n-AND-\n(3) Patient is not receiving Nemluvio in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nemluvio will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Nemluvio therapy\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Patient is not receiving Nemluvio in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocit",
    "alokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\nAuthorization will be issued for 12 months.\nB. Prurigo Nodularis\n1. Initial Authorization\na. Nemluvio will be approved based on both of the following criteria:\n(1) Diagnosis of prurigo nodularis\n-AND-\n(2) Patient is not receiving Nemluvio in combination with Dupixent for treatment of the\nsame indication\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nemluvio will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Nemluvio therapy\n-AND-\n(2) Patient is not receiving Nemluvio in combination with Dupixent for treatment of the\nsame indication\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\n© 2025 UnitedHealthcare Services, Inc.\n2\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limitations may be in place.\n• Medical Necessity may be in place.\n4. References:\n1. Nemluvio [package insert]. Dallas, TX: Galderma Laboratories, L.P., December 2024.\nProgram Prior Authorization/Notification - Nemluvio (nemolizumab-ilto)\nChange Control\n6/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}